Milne Report to MSNZ – The Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis (PPMS) in Aotearoa NZ – 180924

March 28, 2025

Milne Report to MSNZ - The Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis (PPMS) in Aotearoa NZ - 180924